The Checkmate-9LA trial of Opdivo plus Yervoy yesterday read out positively for overall survival.
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
An analysis of stock market movers during the period of this year’s Esmo congress gives biotech watchers little cause for happiness.
Parps show more promise in ovarian and prostate cancers, but Kras disappoints. Here's a round up of Vantage's coverage of the 2019 European Society for Medical…
In prostate cancer Clovis could be adopting a more realistic regulatory stance with its Parp than Astrazeneca and Merck & Co. In the long run will it matter much?
A surprisingly successful study of Opdivo and Yervoy suggests that the enrolment of co-called hyperprogressors could have scuppered other trials.
Lynparza looks set to add a third tumour type to its label, strengthening the grip of Astrazeneca and Merck & Co on the Parp inhibitor market.
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.